Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression to Immunotherapy

NCT07218692 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07218692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression to Immunotherapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
August 11, 2026
Completion date
August 11, 2027
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, advanced renal cell carcinoma, advanced sarcomatoid renal cell carcinoma, metastatic clear cell renal cell carcinoma, metastatic renal cell carcinoma, metastatic sarcomatoid renal cell carcinoma, recurrent renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8